(NASDAQ: CPRX) Catalyst Pharmaceuticals's forecast annual revenue growth rate of 9.07% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.85%.
Catalyst Pharmaceuticals's revenue in 2026 is $596,958,000.On average, 9 Wall Street analysts forecast CPRX's revenue for 2026 to be $79,025,077,964, with the lowest CPRX revenue forecast at $75,155,390,997, and the highest CPRX revenue forecast at $82,736,893,452. On average, 9 Wall Street analysts forecast CPRX's revenue for 2027 to be $87,426,533,065, with the lowest CPRX revenue forecast at $75,897,019,809, and the highest CPRX revenue forecast at $93,535,792,186.
In 2028, CPRX is forecast to generate $94,539,316,320 in revenue, with the lowest revenue forecast at $82,911,898,270 and the highest revenue forecast at $106,231,596,296.